OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide

Product Code DAT16784
Publication Date November 2010
Publisher Datamonitor
Product Type Report
Pages 192
ISBN Number not applicable
Change currency
PDF £630.00 €759 $996 BUY >
PRINT £690 €831 $1,091 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide

Datamonitor's OTC Pharmaceuticals - Top 5 Emerging Markets Industry Guide is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China, India, Mexico and South Africa). The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

  • Contains an executive summary and data on value, volume and segmentation
  • Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies
  • Incorporates in-depth five forces competitive environment analysis and scorecards
  • Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country. .
  • Includes a five-year forecast of the industry

Highlights

The Top 5 Emerging countries contributed $17658.8 million to the global OTC Pharmaceuticals industry in 2009, with a CAGR of 7% between 2005 and 2009

China is the leading country among the Top 5 emerging nations, with market revenues of $9,811. million in 2009.

The China is expected to lead the otc pharmaceuticals industry in the Top five emerging nations, with a value of $13,449.9 in 2014

Why you should buy this report

  • Spot future trends and developments
  • Inform your business decisions
  • Add weight to presentations and marketing materials
  • Save time carrying out entry-level research

Market Definition

The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirinand other analgesics), and medicated skin products (anti-bacteria's, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness).

Contents

  • Table Of Contents
  • About Datamonitor
  • Introduction
    • What is this report about?
    • Who is the target reader?
    • How to use this report
    • Definitions
  • Top 5 Emerging Countries Otc Pharmaceuticals Outlook
  • Otc Pharmaceuticals In South Africa
    • Market overview
    • Market value
    • Market segmentation I
    • Market share
    • Five forces analysis
    • Leading companies
    • Market distribution
    • Market Forecasts
    • Macroeconomic indicators
  • Otc Pharmaceuticals In Brazil
    • Market overview
    • Market value
    • Market segmentation I
    • Market segmentation II
    • Market share
    • Five forces analysis
    • Leading companies
    • Market distribution
    • Market Forecasts
    • Macroeconomic indicators
  • Otc Pharmaceuticals In China
    • Market overview
    • Market value
    • Market segmentation I
    • Market segmentation II
    • Market share
    • Five forces analysis
    • Leading companies
    • Market distribution
    • Market Forecasts
    • Macroeconomic indicators
  • Otc Pharmaceuticals In India
    • Market overview
    • Market value
    • Market segmentation I
    • Market segmentation II
    • Market share
    • Five forces analysis
    • Leading companies
    • Market distribution
    • Market Forecasts
    • Macroeconomic indicators
  • Otc Pharmaceuticals In Mexico
    • Market overview
    • Market value
    • Market segmentation I
    • Market segmentation II
    • Market share
    • Five forces analysis
    • Leading companies
    • Market distribution
    • Market Forecasts
    • Macroeconomic indicators
  • Appendix
    • Data Research Methodology
  • List Of Tables
    • Table 1: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m), 2005-14
    • Table 2: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m), 2005-09
    • Table 3: Top 5 emerging countries otc pharmaceuticals industry forecast, revenue ($m), 2009-14
    • Table 4: South Africa otc pharmaceuticals market value: $ million, 2005-09
    • Table 5: South Africa otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 6: South Africa otc pharmaceuticals market share: % share, by value, 2009
    • Table 7: Pharma Natura (Pty) Ltd: key facts
    • Table 8: Weleda Group: key facts
    • Table 9: Johnson & Johnson: key facts
    • Table 10: Johnson & Johnson: key financials ($)
    • Table 11: Johnson & Johnson: key financial ratios
    • Table 12: South Africa otc pharmaceuticals market distribution: % share, by value, 2009
    • Table 13: South Africa OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 14: South Africa size of population (million), 2005-09
    • Table 15: South Africa gdp (constant 2000 prices, $ billion), 2005-09
    • Table 16: South Africa gdp (current prices, $ billion), 2005-09
    • Table 17: South Africa inflation, 2005-09
    • Table 18: South Africa consumer price index (absolute), 2005-09
    • Table 19: South Africa exchange rate, 2005-09
    • Table 20: Brazil otc pharmaceuticals market value: $ million, 2005-09
    • Table 21: Brazil otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 22: Brazil otc pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 23: Brazil otc pharmaceuticals market share: % share, by value, 2009
    • Table 24: Johnson & Johnson: key facts
    • Table 25: Johnson & Johnson: key financials ($)
    • Table 26: Johnson & Johnson: key financial ratios
    • Table 27: Sanofi-Aventis: key facts
    • Table 28: Sanofi-Aventis: key financials ($)
    • Table 29: Sanofi-Aventis: key financials (€)
    • Table 30: Sanofi-Aventis: key financial ratios
    • Table 31: Abbott Laboratories: key facts
    • Table 32: Abbott Laboratories: key financials ($)
    • Table 33: Abbott Laboratories: key financial ratios
    • Table 34: Brazil otc pharmaceuticals market distribution: % share, by value, 2009
    • Table 35: Brazil OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 36: Brazil size of population (million), 2005-09
    • Table 37: Brazil gdp (constant 2000 prices, $ billion), 2005-09
    • Table 38: Brazil gdp (current prices, $ billion), 2005-09
    • Table 39: Brazil inflation, 2005-09
    • Table 40: Brazil consumer price index (absolute), 2005-09
    • Table 41: Brazil exchange rate, 2005-09
    • Table 42: China otc pharmaceuticals market value: $ million, 2005-09
    • Table 43: China otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 44: China otc pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 45: China otc pharmaceuticals market share: % share, by value, 2009
    • Table 46: Johnson & Johnson: key facts
    • Table 47: Johnson & Johnson: key financials ($)
    • Table 48: Johnson & Johnson: key financial ratios
    • Table 49: Novartis AG: key facts
    • Table 50: Novartis AG: key financials ($)
    • Table 51: Novartis AG: key financial ratios
    • Table 52: Chengdu Rosun Antiseptic Pharmaceutical Co., Ltd: key facts
    • Table 53: China otc pharmaceuticals market distribution: % share, by value, 2009
    • Table 54: China OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 55: China size of population (million), 2005-09
    • Table 56: China gdp (constant 2000 prices, $ billion), 2005-09
    • Table 57: China gdp (current prices, $ billion), 2005-09
    • Table 58: China inflation, 2005-09
    • Table 59: China consumer price index (absolute), 2005-09
    • Table 60: China exchange rate, 2005-09
    • Table 61: India otc pharmaceuticals market value: $ million, 2005-09
    • Table 62: India otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 63: India otc pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 64: India otc pharmaceuticals market share: % share, by value, 2009
    • Table 65: Cipla Ltd: key facts
    • Table 66: Cipla Ltd: key financials ($)
    • Table 67: Cipla Ltd: key financials (Rs.)
    • Table 68: Cipla Ltd: key financial ratios
    • Table 69: Johnson & Johnson: key facts
    • Table 70: Johnson & Johnson: key financials ($)
    • Table 71: Johnson & Johnson: key financial ratios
    • Table 72: GlaxoSmithKline Plc: key facts
    • Table 73: GlaxoSmithKline Plc: key financials ($)
    • Table 74: GlaxoSmithKline Plc: key financials (£)
    • Table 75: GlaxoSmithKline Plc: key financial ratios
    • Table 76: India otc pharmaceuticals market distribution: % share, by value, 2009
    • Table 77: India OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 78: India size of population (million), 2005-09
    • Table 79: India gdp (constant 2000 prices, $ billion), 2005-09
    • Table 80: India gdp (current prices, $ billion), 2005-09
    • Table 81: India inflation, 2005-09
    • Table 82: India consumer price index (absolute), 2005-09
    • Table 83: India exchange rate, 2005-09
    • Table 84: Mexico otc pharmaceuticals market value: $ million, 2005-09
    • Table 85: Mexico otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Table 86: Mexico otc pharmaceuticals market segmentation II: % share, by value, 2009
    • Table 87: Mexico otc pharmaceuticals market share: % share, by value, 2009
    • Table 88: Bayer AG: key facts
    • Table 89: Bayer AG: key financials ($)
    • Table 90: Bayer AG: key financials (€)
    • Table 91: Bayer AG: key financial ratios
    • Table 92: Johnson & Johnson: key facts
    • Table 93: Johnson & Johnson: key financials ($)
    • Table 94: Johnson & Johnson: key financial ratios
    • Table 95: Boehringer Ingelheim GmbH: key facts
    • Table 96: Boehringer Ingelheim GmbH: key financials ($)
    • Table 97: Boehringer Ingelheim GmbH: key financials (€)
    • Table 98: Boehringer Ingelheim GmbH: key financial ratios
    • Table 99: Mexico otc pharmaceuticals market distribution: % share, by value, 2009
    • Table 100: Mexico OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Table 101: Mexico size of population (million), 2005-09
    • Table 102: Mexico gdp (constant 2000 prices, $ billion), 2005-09
    • Table 103: Mexico gdp (current prices, $ billion), 2005-09
    • Table 104: Mexico inflation, 2005-09
    • Table 105: Mexico consumer price index (absolute), 2005-09
    • Table 106: Mexico exchange rate, 2005-09
  • List Of Figures
    • Figure 1: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m), 2005-14
    • Figure 2: Top 5 emerging countries otc pharmaceuticals industry, revenue ($m), 2005-09
    • Figure 3: Top 5 emerging countries otc pharmaceuticals industry forecast, revenue ($m), 2009-14
    • Figure 4: South Africa otc pharmaceuticals market value: $ million, 2005-09
    • Figure 5: South Africa otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 6: South Africa otc pharmaceuticals market share: % share, by value, 2009
    • Figure 7: Forces driving competition in the otc pharmaceuticals market in South Africa, 2009
    • Figure 8: Drivers of buyer power in the otc pharmaceuticals market in South Africa, 2009
    • Figure 9: Drivers of supplier power in the otc pharmaceuticals market in South Africa, 2009
    • Figure 10: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in South Africa, 2009
    • Figure 11: Factors influencing the threat of substitutes in the otc pharmaceuticals market in South Africa, 2009
    • Figure 12: Drivers of degree of rivalry in the otc pharmaceuticals market in South Africa, 2009
    • Figure 13: Johnson & Johnson: revenues & profitability
    • Figure 14: Johnson & Johnson: assets & liabilities
    • Figure 15: South Africa otc pharmaceuticals market distribution: % share, by value, 2009
    • Figure 16: South Africa OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 17: Brazil otc pharmaceuticals market value: $ million, 2005-09
    • Figure 18: Brazil otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 19: Brazil otc pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 20: Brazil otc pharmaceuticals market share: % share, by value, 2009
    • Figure 21: Forces driving competition in the otc pharmaceuticals market in Brazil, 2009
    • Figure 22: Drivers of buyer power in the otc pharmaceuticals market in Brazil, 2009
    • Figure 23: Drivers of supplier power in the otc pharmaceuticals market in Brazil, 2009
    • Figure 24: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Brazil, 2009
    • Figure 25: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Brazil, 2009
    • Figure 26: Drivers of degree of rivalry in the otc pharmaceuticals market in Brazil, 2009
    • Figure 27: Johnson & Johnson: revenues & profitability
    • Figure 28: Johnson & Johnson: assets & liabilities
    • Figure 29: Sanofi-Aventis: revenues & profitability
    • Figure 30: Sanofi-Aventis: assets & liabilities
    • Figure 31: Abbott Laboratories: revenues & profitability
    • Figure 32: Abbott Laboratories: assets & liabilities
    • Figure 33: Brazil otc pharmaceuticals market distribution: % share, by value, 2009
    • Figure 34: Brazil OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 35: China otc pharmaceuticals market value: $ million, 2005-09
    • Figure 36: China otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 37: China otc pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 38: China otc pharmaceuticals market share: % share, by value, 2009
    • Figure 39: Forces driving competition in the otc pharmaceuticals market in China, 2009
    • Figure 40: Drivers of buyer power in the otc pharmaceuticals market in China, 2009
    • Figure 41: Drivers of supplier power in the otc pharmaceuticals market in China, 2009
    • Figure 42: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in China, 2009
    • Figure 43: Factors influencing the threat of substitutes in the otc pharmaceuticals market in China, 2009
    • Figure 44: Drivers of degree of rivalry in the otc pharmaceuticals market in China, 2009
    • Figure 45: Johnson & Johnson: revenues & profitability
    • Figure 46: Johnson & Johnson: assets & liabilities
    • Figure 47: Novartis AG: revenues & profitability
    • Figure 48: Novartis AG: assets & liabilities
    • Figure 49: China otc pharmaceuticals market distribution: % share, by value, 2009
    • Figure 50: China OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 51: India otc pharmaceuticals market value: $ million, 2005-09
    • Figure 52: India otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 53: India otc pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 54: India otc pharmaceuticals market share: % share, by value, 2009
    • Figure 55: Forces driving competition in the otc pharmaceuticals market in India, 2009
    • Figure 56: Drivers of buyer power in the otc pharmaceuticals market in India, 2009
    • Figure 57: Drivers of supplier power in the otc pharmaceuticals market in India, 2009
    • Figure 58: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in India, 2009
    • Figure 59: Factors influencing the threat of substitutes in the otc pharmaceuticals market in India, 2009
    • Figure 60: Drivers of degree of rivalry in the otc pharmaceuticals market in India, 2009
    • Figure 61: Cipla Ltd: revenues & profitability
    • Figure 62: Cipla Ltd: assets & liabilities
    • Figure 63: Johnson & Johnson: revenues & profitability
    • Figure 64: Johnson & Johnson: assets & liabilities
    • Figure 65: GlaxoSmithKline Plc: revenues & profitability
    • Figure 66: GlaxoSmithKline Plc: assets & liabilities
    • Figure 67: India otc pharmaceuticals market distribution: % share, by value, 2009
    • Figure 68: India OTC pharmaceuticals market value forecast: $ million, 2009-14
    • Figure 69: Mexico otc pharmaceuticals market value: $ million, 2005-09
    • Figure 70: Mexico otc pharmaceuticals market segmentation I:% share, by value, 2009
    • Figure 71: Mexico otc pharmaceuticals market segmentation II: % share, by value, 2009
    • Figure 72: Mexico otc pharmaceuticals market share: % share, by value, 2009
    • Figure 73: Forces driving competition in the otc pharmaceuticals market in Mexico, 2009
    • Figure 74: Drivers of buyer power in the otc pharmaceuticals market in Mexico, 2009
    • Figure 75: Drivers of supplier power in the otc pharmaceuticals market in Mexico, 2009
    • Figure 76: Factors influencing the likelihood of new entrants in the otc pharmaceuticals market in Mexico, 2009
    • Figure 77: Factors influencing the threat of substitutes in the otc pharmaceuticals market in Mexico, 2009
    • Figure 78: Drivers of degree of rivalry in the otc pharmaceuticals market in Mexico, 2009
    • Figure 79: Bayer AG: revenues & profitability
    • Figure 80: Bayer AG: assets & liabilities
    • Figure 81: Johnson & Johnson: revenues & profitability
    • Figure 82: Johnson & Johnson: assets & liabilities
    • Figure 83: Boehringer Ingelheim GmbH: revenues & profitability
    • Figure 84: Boehringer Ingelheim GmbH: assets & liabilities
    • Figure 85: Mexico otc pharmaceuticals market distribution: % share, by value, 2009
    • Figure 86: Mexico OTC pharmaceuticals market value forecast: $ million, 2009-14